Compounded Sema Injectable denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Limits Quantity — and Why You Can Appeal

UnitedHealthcare applies quantity limits to compounded semaglutide injectable as a utilization-management tool. The plan sets a maximum allowable supply or fill frequency, and claims that exceed those limits are rejected automatically — without individual clinical review of whether the prescribed quantity is appropriate for your treatment plan. This means the denial was generated by the plan's claims system, not by a physician reviewing your case.

Quantity-limit denials are appealable, and they are frequently overturned when the prescriber documents why the medically necessary quantity differs from the plan's default limit.

## Your Federal Appeal Rights

Under ACA §2719 you are entitled to independent external review after exhausting UHC's internal appeals. Under ERISA §503 (employer-sponsored plans) you are entitled to a full-and-fair review with access to the criteria the plan used. The external-review window is generally open for approximately four months after a final internal denial. If your condition makes delay a health risk, request an expedited 72-hour review.

## The Concrete Appeal Process

1. Request UHC's published quantity-limit criteria for compounded GLP-1 injectables in writing. 2. Confirm with your prescriber the clinical rationale for the prescribed quantity (e.g., titration schedule, dose escalation, clinical condition). 3. File a Level 1 internal appeal with a prescriber letter and supporting chart documentation. 4. If denied, escalate to Level 2 and then to external IRO review, which is binding on UHC.

## Documentation to Gather

• Diagnosis confirmation — chart notes, diagnostic codes, and clinical assessments establishing the underlying condition.
• Prescriber treatment plan — a document (or section of the medical-necessity letter) explaining the intended dosing and titration schedule, and why the prescribed quantity is required to implement that plan safely.
• Clinical severity documentation — chart entries showing the degree of illness and why the standard quantity limit is insufficient for your treatment needs.
• Prior-treatment history — dated records of prior treatments, duration, and outcomes, establishing the clinical context for the current prescription.
• Prescriber medical-necessity letter — should state specifically why the prescribed quantity is medically necessary for this patient, reference the FDA-approved prescribing information or compounding pharmacy documentation regarding the dosing schedule being followed, and explain why the plan's default limit is clinically inadequate for this case.

## Criteria-Mapping Structure

Obtain UHC's quantity-limit exception criteria and address each one directly:

| UHC Quantity-Limit Criterion | Supporting Evidence | |---|---| | [Copy each criterion from UHC's policy verbatim] | [Chart date, prescriber note, or treatment-plan entry that satisfies the criterion] |

The most persuasive quantity-limit appeals combine a clear prescriber-authored treatment plan — showing the titration or dosing rationale — with documentation that the clinical condition requires a supply or frequency beyond the plan's default. When the prescriber explains the "why" behind the quantity, reviewers have a defined clinical rationale to evaluate rather than a bare request for more medication.